Rigel Pharmaceuticals (RIGL) & Its Competitors Head to Head Comparison

Rigel Pharmaceuticals (NASDAQ:RIGL) is one of 846 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Rigel Pharmaceuticals to similar companies based on the strength of its institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rigel Pharmaceuticals and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1	2	3	0	2.33
Rigel Pharmaceuticals Competitors	9904	15277	45619	1595	2.54

Rigel Pharmaceuticals currently has a consensus price target of $66.75, indicating a potential upside of 51.26%. As a group, “Biotechnology” companies have a potential upside of 99.28%. Given Rigel Pharmaceuticals’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Rigel Pharmaceuticals has less favorable growth aspects than its competitors.

Profitability

This table compares Rigel Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	106.59%	14.89%	11.99%
Rigel Pharmaceuticals Competitors	-12,285.98%	-196.04%	-30.61%

Volatility & Risk

Rigel Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals’ competitors have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.

Valuation and Earnings

This table compares Rigel Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28 million	$367.02 million	2.85
Rigel Pharmaceuticals Competitors	$729.47 million	$11.46 million	-14.88

Rigel Pharmaceuticals’ competitors have higher revenue, but lower earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Rigel Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for people with serious hematologic disorders and cancers. Founded in 1996 and based in South San Francisco, California, the company has focused on treatments that target biological pathways involved in disease. Rigel’s marketed products include Tavalisse (fostamatinib), an oral treatment for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment, and Rezlidhia (olutasidenib), an oral therapy for certain adults with relapsed or refractory acute myeloid leukemia containing an IDH1 mutation.